Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.

Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O. · 2009

Read Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT. by Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc2746281.txt.

Description

Dubreuil and co-authors characterized in 2009 masitinib, a new tyrosine kinase inhibitor drug that targets KIT, a receptor that drives growth in mast cells and some tumors. KIT is a target in cancer, mastocytosis, and inflammatory disease, but the standard inhibitor imatinib has limits. A more selective drug might work as well with fewer side effects.

In lab tests masitinib blocked KIT more strongly and selectively than imatinib, and also hit two related kinases while sparing many others. It blocked mast cell degranulation, cytokine output, and migration more strongly, and worked against KIT mutants that sit near the membrane. In mice it blocked growth of tumors carrying such a mutant, with no heart or gene toxicity seen in animal studies.

Catalog record

CREATORDubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE52 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC2746281

Browse the full library · About the Tower of Babel